Skip to main navigation
  Menu

ASLAN Pharmaceuticals

  • Pipeline
  • Our Team
  • Investor Relations
  • News & Publications
  • Contact
EN
english中文

Investor Relations

Investor Relations

  • Investor Home
  • Corporate Information
  • Stock Information
  • News & Events
  • Financial Information
  • Shareholder Services

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Alerts sign up

Required fields denoted by an asterisk ().
Alert type

About ASLAN

About ASLAN

ASLAN Pharmaceuticals is a clinical-stage immunology focused biopharmaceutical company developing innovative treatments to transform the lives of patients.

News Releases
Date Title
Mar 22, 2023
ASLAN Pharmaceuticals to Participate in Fireside Chat at the H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
Mar 14, 2023
ASLAN Pharmaceuticals Announces Acceptance of Two Abstracts for Poster Presentation at the 1st International Societies for Investigative Dermatology Meeting
Mar 10, 2023
ASLAN Pharmaceuticals Announces Plan to Implement ADS Ratio Change
Read More
H.C. Wainwright Autoimmune & Inflammatory Disease Virtual Conference
Mar 30, 2023
Webcast link
Add to Outlook
Add to Google Calendar
Read More

Investor Relations
E-mail: investor@aslanpharma.com

Shareholder Tools

  • Print Page

    Print Page

  • RSS Feeds

    RSS Feeds

  • E-mail Alerts

    E-mail Alerts

Company

  • Pipeline
  • Our Team
  • Investor Relations
  • News & Publications
  • Contact
  • Terms and Conditions

Careers

For more information on employment opportunities at ASLAN, please contact us at careers@aslanpharma.com

Contact Us

Singapore Headquarters
83 Clemenceau Avenue
#12-03 UE Square
Singapore 239920
Tel: +65 6222 4235
Fax: +65 6225 2419

contact@aslanpharma.com